Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PCBM | ISIN: US0144421072 | Ticker-Symbol: 0Z2
Tradegate
27.06.25 | 16:21
1,250 Euro
-0,79 % -0,010
1-Jahres-Chart
ALECTOR INC Chart 1 Jahr
5-Tage-Chart
ALECTOR INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2501,27010:29
1,2501,27027.06.

Aktuelle News zur ALECTOR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.Alector, Inc.: Alector Provides Executive Leadership Update102-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector...
► Artikel lesen
13.06.Alector, Inc. - 8-K, Current Report1
28.03.Alector, Inc.: Alector Provides Executive Leadership Update279--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
10.03.Alector, Inc. - 8-K, Current Report2
26.02.Alector, Inc.: Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update201Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226...
► Artikel lesen
ALECTOR Aktie jetzt für 0€ handeln
26.02.Alector, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
26.02.Alector, Inc. - 10-K, Annual Report-
26.02.Alector, Inc. - 8-K, Current Report-
25.02.Alector Q4 2024 Earnings Preview1
13.01.Alector, Inc.: Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025168Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated...
► Artikel lesen
10.01.AbbVie terminates Alector collaboration agreement12
10.01.Alector, Inc. - 8-K, Current Report-
25.11.24Alector, Inc.: Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update188SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment...
► Artikel lesen
06.11.24Alector, Inc.: Alector Reports Third Quarter 2024 Financial Results and Provides Business Update121Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024 Participant baseline characteristics in pivotal INFRONT-3 Phase 3 trial...
► Artikel lesen
07.08.24Alector, Inc.: Alector Reports Second Quarter 2024 Financial Results and Provides Business Update126Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024 Patient baseline characteristics data for the INVOKE-2 trial confirm the...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1